Opus Genetics (IRD) Competitors $2.05 +0.05 (+2.45%) As of 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IRD vs. RAPT, ALMS, PRTC, GLUE, KRRO, LXEO, SLDB, ATXS, UPXI, and EOLSShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Rapt Therapeutics (RAPT), Alumis (ALMS), PureTech Health (PRTC), Monte Rosa Therapeutics (GLUE), Korro Bio (KRRO), Lexeo Therapeutics (LXEO), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Upexi (UPXI), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. Opus Genetics vs. Its Competitors Rapt Therapeutics Alumis PureTech Health Monte Rosa Therapeutics Korro Bio Lexeo Therapeutics Solid Biosciences Astria Therapeutics Upexi Evolus Rapt Therapeutics (NASDAQ:RAPT) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability. Do insiders & institutionals hold more shares of RAPT or IRD? 99.1% of Rapt Therapeutics shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 2.4% of Rapt Therapeutics shares are held by company insiders. Comparatively, 6.6% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, RAPT or IRD? Rapt Therapeutics has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Do analysts prefer RAPT or IRD? Rapt Therapeutics currently has a consensus price target of $24.78, indicating a potential downside of 10.74%. Opus Genetics has a consensus price target of $7.75, indicating a potential upside of 278.23%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Rapt Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapt Therapeutics 1 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.58Opus Genetics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media prefer RAPT or IRD? In the previous week, Rapt Therapeutics had 5 more articles in the media than Opus Genetics. MarketBeat recorded 11 mentions for Rapt Therapeutics and 6 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.62 beat Rapt Therapeutics' score of 0.47 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapt Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Opus Genetics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, RAPT or IRD? Opus Genetics has higher revenue and earnings than Rapt Therapeutics. Rapt Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapt TherapeuticsN/AN/A-$129.87M-$14.17-1.96Opus Genetics$15.42M7.96-$57.53M-$1.92-1.07 Is RAPT or IRD more profitable? Rapt Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -377.89%. Rapt Therapeutics' return on equity of -67.92% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Rapt TherapeuticsN/A -67.92% -59.59% Opus Genetics -377.89%-384.33%-148.90% SummaryOpus Genetics beats Rapt Therapeutics on 8 of the 15 factors compared between the two stocks. Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$122.51M$3.39B$6.15B$10.47BDividend YieldN/A2.30%5.73%4.78%P/E Ratio-1.0722.9785.0727.24Price / Sales7.96435.83573.51178.32Price / CashN/A46.1137.3961.86Price / Book9.7610.5212.426.70Net Income-$57.53M-$52.47M$3.32B$276.79M7 Day Performance2.96%-0.06%0.28%-0.86%1 Month Performance46.36%15.60%10.06%6.26%1 Year PerformanceN/A15.29%72.23%37.64% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics2.3532 of 5 stars$2.05+2.5%$7.75+278.2%N/A$122.51M$15.42M-1.0714News CoverageAnalyst ForecastRAPTRapt Therapeutics3.3567 of 5 stars$28.74-3.8%$23.50-18.2%+86.7%$473.81MN/A-2.0280Analyst ForecastAnalyst RevisionHigh Trading VolumeALMSAlumis3.5608 of 5 stars$4.47+8.4%$20.17+351.7%-56.7%$468.18M$20.06M0.00N/AHigh Trading VolumePRTCPureTech Health0.1871 of 5 stars$18.61-2.5%N/A-11.7%$459.23M$4.83M0.00100Gap DownGLUEMonte Rosa Therapeutics2.6761 of 5 stars$7.42-3.1%$15.33+106.6%+117.0%$457.33M$75.62M20.5790KRROKorro Bio1.6739 of 5 stars$48.97+12.1%$86.83+77.3%+29.2%$456.97M$6.28M-4.9970News CoverageAnalyst ForecastLXEOLexeo Therapeutics2.776 of 5 stars$8.42+30.1%$17.00+102.0%-1.1%$453.72MN/A-2.5858Analyst ForecastHigh Trading VolumeSLDBSolid Biosciences2.7843 of 5 stars$5.46-0.4%$15.00+174.7%-4.7%$425.55MN/A-1.95100ATXSAstria Therapeutics2.047 of 5 stars$7.46-3.0%$29.50+295.4%+3.7%$421.01MN/A-3.7130Trending NewsAnalyst DowngradeUPXIUpexi2.4417 of 5 stars$7.14-7.3%$15.50+117.1%+132.4%$420.24M$15.81M0.00130Analyst ForecastEOLSEvolus4.0264 of 5 stars$6.26-2.7%$21.25+239.7%-60.4%$403.96M$277.94M-6.37170Analyst Forecast Related Companies and Tools Related Companies Rapt Therapeutics Alternatives Alumis Alternatives PureTech Health Alternatives Monte Rosa Therapeutics Alternatives Korro Bio Alternatives Lexeo Therapeutics Alternatives Solid Biosciences Alternatives Astria Therapeutics Alternatives Upexi Alternatives Evolus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRD) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredThe Final DisplacementA new documentary called The Final Displacement is stirring major controversy — and for good reason. It expose...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
